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INTRODUCTION
In Hodgkin’s disease, each clinical or pathologic
stage can be related to the extent of the area involved
and predicts the next anatomical region at risk for tu-
mor dissemination. Thus, the Ann Arbor staging crite-
ria1,2 are useful in planning treatment and determin-
ing the evolution of the disease. However, the biologi-
cal behavior of non-Hodgkin lymphomas (NHL) is
much more complex in relation to their presentation
and natural history. In this way, discrepancies between
NHL found in the various subgroups make it impos-
sible to analyze them all together, and in particular
we cannot predict survival based only on the anatomi-
cal areas involved.
Age, general condition at the time of diagnosis,
serum lactate dehydrogenase (LDH) level, extranodal
involvement and tumor burden assessment are the
factors that have been shown to have prognostic value
for survival in many studies.3-7 There are some varia-
tions between the different authors. We studied all
these parameters in order to understand better which
of these could predict survival among a set of patients
of low socioeconomic level treated in a public hospi-
tal in the city of São Paulo.
METHODS
An initial analysis of 142 patients with NHL was
made, whose biopsies were reviewed and classified in
accordance with the Working Formulation (WF)8 between
February 1988 and March 1993 in our institution. From
this, 29 patients were excluded due ineligible data,
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8plete and differential blood cell count; biochemistry
test, particularly the LDH level; chest x-ray; chest, ab-
domen and pelvis CT scans; and bilateral bone mar-
row biopsies. Some special procedures such as lum-
bar puncture, brain CT or percutaneous liver biopsy
were performed only if there was clinical suspicion of
local involvement. Each patient was characterized us-
ing the following remission criteria after treatment:
complete remission (CR), defined as a complete ab-
sence of any clinical or laboratory (biochemical or ra-
diological) signs of disease maintained for at least four
sequential weeks; partial remission (PR), defined as a
reduction in tumor burden of 50% or more, measur-
able in two dimensions at the same time; refractory
disease (RD), defined as a reduction in tumor burden
of less than 50% compared with the original size, or a
complete failure of response to treatment, or evidence
of growing tumor burden during two sequential
therapy cycles. The disease free-survival (DFS) was
taken as the length of time between CR and the last
consultation or the relapse. The overall survival (OS)
used the same criteria for all patient situations.
The following clinical variables were evaluated:
age in years; sex; race; general condition (performance
status) in accordance with the Eastern Cooperative
Oncology Group (ECOG);8 extranodal site involvement;
presence of bulk disease defined as a tumor burden
mass larger than 10 cm in one diameter or occupying
more than one third of the mediastinum; and CNS
involvement. The LDH level was scored at three lev-
els: ≤ 225 U/dl; > 225 and < 450 U/dl; and ≥ 450 U/dl.
Biopsies from different disease sites, mostly lymphoid
nodes, were reviewed in the Pathology Department and
reclassified according to the WF. When there were
plenty of samples, immunohistological studies were
done on the B (CD-20) and T (CD45RO) markers using
the ABC method.9 The clinical stages were determined
in accordance with the Ann Arbor classification. Seven
different, non-randomized chemotherapy regimens
were used. These were chosen based on the initial WF
histological classification. The second and third gen-
eration schemes such as Macop-B,7 Promace-
CYTAbom8 and the BFM-83 high-risk protocol9 were
used for high grade groups. CHOP,10 BACOP10 and
MVPP11 were used for intermediate groups. For low
grade lymphoma, COP11 and MVPP11 were the most
often used protocols.
Statistical Methods. Survival curves were plotted
according to the method of Kaplan and Meier.12 Sta-
tistical significance among curves was determined by
the Cox-Mantel method, measuring variables with two
categories of results, and the generalized Wilcoxon test
leaving the 113 patients that constituted our first study.
A second analysis was carried out on 93 patients who
completed their follow-up and could be evaluated as
regards their treatment.
The staging of the disease were done before and
after treatment. The tests performed included: com-
Table 1- Characteristics of patients
with high grade lymphoma
1st  analysis 2nd analysis
Variables nºpatients    P-value nº patients P-value
Histological subset
Immunoblastic 12 0.42 09 0.54
SNCC 02 01
Lymphoblastic 03 03
Unclassified 04 03
Sex
Female 05 0.06 11 0.15
Male 16 05
Age (years)
< 60 19 0.92 14 0.42
> 60 02 02
Race
White 15 0.04 11 0.07
Black 04 04
Yellow 02 01
B symptoms
Present 13 0.15 09 0.62
Absent 08 07
Performance status
0 03 <0.01 02 0.52
1 12 10
2 04 03
3 04 01
4 01 00
Stage
I 02 0.09 02 0.13
II 07 04
III 06 05
IV 06 05
Extranodal disease
Present 03 <0.01 03 0.06
Absent 18 13
Bulk disease
Present 10 0.63 08 0.48
Absent 11 08
Mediastinal disease
Present 06 0.63 04 0.87
Absent 15 12
CNS involvement
Present 01 0.14 01 <0.01
Absent 16 15
BM infiltration
Present 05 0.30 04 0.17
Absent 16 12
Level of DHL
≤ 225 U/dl 04 0.88 04 0.14
>225 and <450 U/dl 06 05
≥ 450 U/dl 04 02
Immunophenotype
B 09 0.50 06 0.65
T 01 01
SNCC = malignant lymphoma small non-cleaved cell; DSCC = malig-
nant lymphoma diffuse small cleaved cell; DMSLC = malignant lym-
phoma diffuse mixed small and large cell; DLC = malignant lymphoma
diffuse large cell; FMSCLC = malignant lymphoma follicular mixed small
cleaved and large cell; BM = bone marrow.
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9for those variables with more than two categories of
results.
RESULTS
Patients’ parameters in relation to the grade of
lymphoma are shown in Tables 1 to 3 and the distri-
bution of the 93 treated patients among the different
chemotherapy schemes is shown in Table 4.
The remission rates for high-grade lymphomas
were: 62% CR, 25% PR and 12% RD; for the intermedi-
ate group: 50% CR, 27% PR and 23% RD; and for the
low grade group: 44% CR, 32% PR and 24% RD. MACOP-
B and CHOP were the treatments analyzed for high
grade lymphoma and their CR were 66% and 40% re-
spectively (P = 0.777). For the intermediate grade, the
Table 3 - Characteristics of patients
with low grade lymphomas
1st  analysis 2nd analysis
Variables nºpatients    P-value nº patients P-value
Histological  subtype
FMSCLC 12 0.02 11 0.29
Lymphoplasmocytoid 03 02
Small  Lymphocytes 12 12
Sex
Female 11 0.14 10 0.19
Male 16 15
Age (years)
< 60 24 0.98 23 0.45
> 60 03 02
Race
White 18 0.21 17 0.15
Black 09 08
B Symptoms
Present 20 0.10 19 0.06
Absent 07 06
Performance Status
0 04 0.21 04 0.21
1 14 14
2 07 05
3 02 02
4 00 00
Stage
I 03 0.26 03 0.26
II 03 03
III 07 07
IV 14 14
Extranodal disease
Present 07 0.62 05 0.48
Absent 20 20
Bulk disease
Present 04 0.65 04 0.7702
Absent 23 21
Mediastinal disease
Present 10 0.29 10 0.52
Absent 17 15
CNS involvement
Present 02 0.56 02 0.56
Absent 13 13
BM infiltration
Present 11 0.94 08 0.79
Absent 16 0.94 17
Level of  DHL
≤l 250 U/dl 06 0.69 06 0.69
>250 and <450 U/dl 08 08
≥ 450 U/dl 05 05
Immunophenotype
B 18 0.42 16 0.60
T 03 03
NCC = malignant lymphoma small non-cleaved cell; DSCC = malig-
nant lymphoma diffuse small cleaved cell; DMSLC = malignant lym-
phoma diffuse mixed small and large cell; DLC = malignant lymphoma
diffuse large cell; FMSCLC = malignant lymphoma follicular mixed small
cleaved and large cell; BM = bone marrow
Table 2- Characteristics of patients with
intermediate grade lymphomas
1st  analysis 2nd analysis
Variables nºpatients    P-value nº patients P-value
Histological subset
DSCC 26 0.22 20 0.54
DMSLC 21 17
DLC 18 15
Sex
Female 34 0.29 28 0.25
Male 31 24
Age (years)
< 60 47 0.96 41 0.13
> 60 18 11
Race
White 43 0.09 34 0.68
Black 22 18
B Symptoms
Present 43 <0.01 34 <0.01
Absent 22 18
Performance status
0 09 <0.01 06 0.02
1 38 33
2 14 11
3 02 02
4 02
Stage
I 02 0.42 01 0.29
II 19 17
III 16 12
IV 28 22
Extranodal disease
Present 34 0.48 30 0.36
Absent 31 22
Bulk disease
Present 39 0.11 30 0.07
Absent 26 20
Mediastinal Disease
Present 20 0.87 18 0.65
Absent 45 34
CNS involvement
Present 04 <0.01 04 <0.01
Absent 39 39
BM Infiltration
Present 24 0.17 36 0.09
Absent 40 16
Level of DHL
≤l 250 U/dl 14 0.06 10 0.14
>250 and <450 U/dl 27 24
≥ 450 U/dl 12 09
Immunophenotype
B 31 0.50 23 0.24
T 07 05
NCC = malignant lymphoma small non-cleaved cell; SCC = malignant
lymphoma diffuse small cleaved cell; DMSLC = malignant lymphoma
diffuse mixed small and large cell; DLC = malignant lymphoma diffuse
large cell; FMSCLC = malignant lymphoma follicular mixed small cleaved
and large cell; BM = bone marrow
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rate of CR to the protocols analyzed were: CHOP 61%,
BACOP 41% and MACOP-B 50% (P = 0.1642). The me-
dian 5-year survival rates were: OS 62% and DFS 52%
for high grade lymphoma, 57% and 49% for intermedi-
ate grade and 63% and 52% for low grade lymphoma
respectively.
DISCUSSION
We analyzed patients with NHL divided into
three subgroups in accordance with the WF classifica-
tion and evaluated the variables that could demon-
strate prognostic value. A second statistical study was
done to check the influence of treatment on the sur-
vival for each variable studied at the first step.
The intermediate grade lymphomas presented
results comparable to those described in the litera-
ture, probably because this was the largest group of
patients. In this group the variables associated with
worse prognosis were: B symptoms (P< 0.01); perfor-
mance status III and IV  (P< 0.01) and CNS involve-
ment (P = 0.006). There are reports that patients with
a diagnosis of performance status of III and IV is re-
lated to high cell proliferation and this fact could have
implications of an unfavorable prognosis.14 It is well
known that better therapeutic results are associated
with longer survival in patients that have a good per-
formance status at the diagnosis.5-7,13
Involvement of the CNS generally implies fre-
quently relapsing disease.15 Some studies have sug-
gested that patients with bone marrow involvement
have a higher risk of presenting CNS infiltration.15 This
aspect was observed in our study.
The small number of patients with high and low
grade lymphomas made it impossible to demonstrate
statistically some important variables reported else-
where such as: bone marrow and CNS involvement,
bulk disease, mediastinal disease, high levels of LDH
and age above 60 years.15
For high grade lymphomas the following vari-
ables were related to worse disease: yellow race (P =
0.003), ECOG III and IV (P < 0.01) and extranodal dis-
ease  (P < 0.01). After including the treatment, the only
variable associated with an unfavorable prognosis for
survival was CNS infiltration (P < 0.01). Many reports
have demonstrated that extranodal disease, especially
if there are two or more involved sites, is associated
with worse evolution.3,16 This is valid for all kinds of
lymphomas. This fact, even if negated by others, makes
us think that it may be necessary to have other factors
associated with the extranodal disease in order to
cause a worse prognosis.5,6 For low grade lymphomas,
only the lymphoplasmocytoid subset (P = 0.018) had
prognostic value, and in the second study no variable
was associated with treatment and survival.
The overall survival and DFS for all grades of
the WF classification are quite similar to those of other
studies, although our patients were treated with dif-
ferent non-randomized protocols. Costa et al.7 had an
OS of 54% and a 5-year DFS of 52% in a series of 54
high and intermediate grade lymphomas, most of
which with diffuse histological patterns and advanced
stage disease. Klimo & Connors17 found a median 8-
year survival of 62% and a DFS of 52% in 126 patients
with diffuse large cell lymphoma. For the low-grade
lymphoma, the OS and DFS were comparable to the
many other studies that included patients with ad-
vanced stage disease.3
A relationship between a high level of LDH and
a worse survival for NHL has very often been re-
ported.5,14,18 Schneider et al.21 pointed out the impor-
tance of this marker even when not considering the
extent of the tumor nor the bulk mass burden. In our
intermediate group, an LDH higher than 450U/dl had
some relation with survival, with a p-value close to
significance (P = 0.055).
Bone marrow involvement was not related to
unfavorable survival in the three studied groups. We
analyzed the presence or absence of focal or diffuse
infiltration. For the intermediate grade lymphomas,
there was a tendency towards diffuse marrow involve-
ment and worse survival (P = 0.086). Data from the
National Cancer Institute, Bethesda, USA, has postu-
lated that marrow involvement means a poor prog-
nostic factor for survival. A similar analysis performed
at the M.D. Anderson Hospital was not able to predict
this variable as an unfavorable factor. However, the
association of bone marrow involvement, high LDH
level and a high rate of cellular proliferation seems to
have some prognostic meaning.14 In both of our sta-
tistical analyses immunological phenotyping did not
Table 4- Distribution of 93 patients with non-hodgkin
lymphomas according to the treatment received
Lymphoma grade
High Intermediate Low
Macop-B 6 14 4
Promace-CytaBOM 1 7 3
BFM-83 1 3 3
MVPP 1 12 2
BACOP 2 13 8
CHOP 5 2 2
Total 16 52 25
Comparisons between types of treatment in each lymphoma grade.
High P=0.7;Intermediate P=0.16; Low P=0.27
Sao Paulo Med J/Rev Paul Med 2000; 118(1):7-12.
11
influence the survival of the three different groups.
Our treatment was based on the first histologi-
cal WF classification, but 43 of the 113 evaluated pa-
tients from the first study had their histological sub-
type changed after review. Thus, the philosophy of bas-
ing treatment on the initial diagnosis generated a mis-
cellany of analyses. Despite having a small sample size,
especially when analyzing each chemotherapy scheme
in isolation, our data are similar to those in other re-
ports.8,20 Although MACOP-B seems to be better than
CHOP for CR rates, we can conclude that they are simi-
lar when considering OS and DFS. This conclusion has
been confirmed by other reports in the last five years.21
For the largest group, the intermediate lympho-
mas, there were no differences between CHOP, BACOP
and MACOP-B relating to survival (P = 0.1642). When
considered separately, CHOP showed a better rate of
CR, 8/13 (61.50%), but this was not significant. At
present, there is a world trend to use CHOP as the
treatment schedule for aggressive lymphoma due to
results that are similar and comparable to more toxic
third-generation protocols.7,8,13
For low-grade lymphomas our results are slightly
inferior to those of other reports, but are comparable
to studies that included advanced stage disease.22
Even though 28% of those patients were treated with
third-generation schemes and the others with CHOP,
BACOP, MVPP or COP, no chemotherapy scheme was
seen to be superior in relation to the prognosis (P =
0.2717). New treatment forms are being used for low-
grade lymphomas, especially purine analogs, inter-
feron and allogeneic and autologous bone marrow
transplantation. However their efficacy is still limited
when compared with classic treatments such as us-
age of alkylating agents or aggressive chemo-
therapy.23,24 We believe that new studies and proto-
cols are necessary in order to have a more precise con-
clusion about the best treatment for low grade lym-
phomas.25
A new attempt at classifying NHL has recently
been made. In this new classification, lymphopro-
liferative disorders are divided into B, T or NK dis-
eases.26 The cytogenetic characteristics and oncogen-
esis with their respective molecular rearrangements
are considered in trying to describe each known pa-
thology as an isolated entity. It is designated the REAL
classification, signifying a consensus between Ameri-
can, European and Asian hemato-pathologists. This
classification appears to have achieved the ideal, but
more time and experience will be required before
reaching a definitive conclusion on such a complex
subject.
It is clear that we need to bring together clinical
hematologists, pathologists and cytogeneticists in
Brazil, in order attain a better understanding of the
complex setting of this disease. Cooperation between
institutions in different areas of the country could
achieve clinical and therapeutic results. Only in this
way will there be a commonality of spirit leading to a
better understanding of NHL in Brazil.
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resumo
CONTEXTO: Na doença de Hodgkin, cada estágio clínico ou
patológico pode ser relacionado com a extensão da área envolvida
e predizer a próxima região anatômica de risco para disseminação.
OBJETIVO: Estabelecer os fatores prognósticos que melhor predizem
sobrevida em LNH.
TIPO DE ESTUDO: Estudo retrospectivo
LOCAL: Disciplina de Hematologia e Hemoterapia, Universidade Fed-
eral de São Paulo - Escola Paulista de Medicina.
PARTICIPANTES: 142 pacientes com LNH diagnosticados entre
fevereiro de 1988 e março de 1993.
VARIÁVEIS ESTUDADAS: Tipo histológico, sexo, idade, raça,
sintomas, sitação “performance”, estágio, doença extranodal,
desenvolvimento de Bulk, comprometimento mediastinal,
envolvimento do SNC, infiltração da medúla óssea, nível de
desidrogenose láctica, fenótipo imune.
RESULTADOS: Ao primeiro estudo (113 pacientes), as seguintes
variáveis tiveram uma pior influência na sobrevida: raça amarela
(P<0.1); ECOG II, III e IV (P<0.1) e doença extranodal (P<0.1) para
os linfomas de alto grau; sintomas constitucionais (P<0.1), ECOG
II, III e IV (P<0.1) e envolvimento de SNC (P<0.1) para os linfomas
de grau intermediário e o subtipo linfoplasmocitóide (P=0.0186)
para os linfomas de baixo grau. Ao segundo estudo (93 pacientes),
quando inclui-se o tratamento, as variáveis relacionadas a sobrevida
foram : envolvimento de SNC (P<0.1) para o linfomas de alto grau;
sintomas constitucionais (P<0.1),  ECOG II, III, IV (P=0.0185) e
envolvimento de SNC (P<0.1) para o grupo intermediário. Nenhuma
variável relacionou-se com a sobrevida para os linfomas de baixo
grau.
CONCLUSÕES: Os linfomas de grau intermediário, provavelmente
devido ao maior número de pacientes, foram mais compatíveis com
os dados encontrados na literatura. Neste caso específico, o
tratamento não influenciou a sobrevida.
PALAVRAS-CHAVE: Linfoma não-Hodgkin. Fatores prognóstico.
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